The cost-benefit of utilizing post-dialysis haemoglobin for dosing of erythropoiesis-stimulating agent therapy in patients with anaemia on haemodialysis in a low-resource setting
Open Access
- 1 January 2026
- journal article
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 8 (1) , 1-6
Abstract
Background: Access to dialysis in South Africa is limited by budgetary constraints. Erythropoiesis-stimulating agents (ESAs) are used to manage anaemia in dialysis patients but are significant cost drivers. We aimed to evaluate haemoglobin and weight variation during dialysis and to assess whether using post-dialysis haemoglobin rather than pre-dialysis haemoglobin was associated with ESA dose reduction and cost benefit. Methods: In this single-centre cross-sectional study, haemoglobin and weight differences before and after a 4-hour mid-week maintenance haemodialysis session were compared. The ESA doses required to maintain haemoglobin levels within the recommended range of 10 – 11.5g/dL were calculated based on the pre- and post-dialysis haemoglobin results, and the difference was used to determine the cost benefit. Results: Fifty-five patients on chronic haemodialysis at a tertiary hospital in Johannesburg, South Africa, were enrolled. The mean post-dialysis haemoglobin was higher than pre-dialysis haemoglobin (11.34±1.75 vs 10.92±1.45g/dL, p=0.003), representing a 3.95% mean haemoglobin increase. The mean intradialytic weight reduction was 3.32±1.68%, pConclusion: In an environment where dialysis access is limited by resource constraints, ESA dosing based on post-dialysis haemoglobin concentrations may translate into significant cost savings. Larger studies are required to validate this approach and assess long-term patient outcomes.Keywords
This publication has 26 references indexed in Scilit:
- Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999–2018 National Health and Nutrition Examination SurveyClinical Kidney Journal, 2022
- Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?Pharmacoepidemiology and Drug Safety, 2020
- Determination of functional iron deficiency status in haemodialysis patients in central South AfricaInternational Journal of Laboratory Hematology, 2016
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2016
- Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression AnalysisAmerican Journal of Kidney Diseases, 2013
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Cognitive Impairment in Chronic Kidney DiseaseJournal of the American Geriatrics Society, 2004
- Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patientsAmerican Journal of Kidney Diseases, 2002
- Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapyAmerican Journal of Kidney Diseases, 2002
- Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?Nephrology Dialysis Transplantation, 1999